Metformin prevents the doxorubicin-induced cardiomyocytes loss

A tétel rövid nézete
dc.contributor.advisorLekli, István
dc.contributor.advisorSzőke, Kitti
dc.contributor.advisordeptDepartment of Pharmacologyhu_HU
dc.contributor.authorPham Le Khanh, Ha
dc.contributor.departmentDE--Gyógyszerésztudományi Karhu_HU
dc.contributor.opponentFehér, Pálma
dc.contributor.opponentCzompa, Attila
dc.contributor.opponentdeptDebreceni Egyetem::Gyógyszerésztudományi Karhu_HU
dc.date.accessioned2017-05-15T07:37:29Z
dc.date.available2017-05-15T07:37:29Z
dc.date.created2017-03-08
dc.description.abstractDoxorubicin is a strong antineoplastic agent which can affects intensely on cells during the treatment. Metformin were shown to possess cardioprotective effect. This cardiactoxicity can be reduced after we treat these cells with Metformin. The cells were survived more under the DOX treatment with the help of Metformin. The aim of this study is to determine the extent to which MET can prevent the autophagy of DOX-induced cells toxicity. In short, result of this work may figure out the usefulness of Metformin and further improve the quality for pathological situations which use Doxorubicin in treatment.hu_HU
dc.description.correctorVÁ
dc.description.correctorgj
dc.description.coursegyógyszerészhu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent30hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/240338
dc.language.isoenhu_HU
dc.subjectmetforminhu_HU
dc.subjectdoxorubicin-induced cardiomyocytes loss
dc.subjectdoxorubicin-induced cardiactoxicty prevention
dc.subject.dspaceDEENK Témalista::Orvostudomány::Gyógyszerésztudományhu_HU
dc.titleMetformin prevents the doxorubicin-induced cardiomyocytes losshu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Pharmacy)